Form 4: Inmune Bio Director's Options Repriced to $1.50

Inmune Bio, Inc. director Scott Juda's stock options were repriced to $1.50 per share following stockholder approval.

Summary

• Scott Juda, a Director of Inmune Bio, Inc. (INMB), had a one-time repricing of certain outstanding stock options.
• The repricing, effective November 18, 2025, was approved by the Issuer's stockholders.
• The per share exercise price of the repriced options was reduced to $1.50, matching the closing price of INMB common stock on The Nasdaq Capital Market on the repricing date.
• A total of 365,000 stock options were repriced, originally granted under the 2017, 2019, and 2021 Stock Incentive Plans.
• Original exercise prices for these options ranged from $3.91 to $24.82 per share.
• All other terms and conditions of the repriced options, including vesting and term, remain unchanged.

Sentiment

Score: 3

Explanation: The repricing of stock options at a significantly lower strike price, while beneficial for the director, reflects a substantial decline in the company's stock value since the original grant dates. This action, though approved by stockholders, can be viewed negatively by existing shareholders due to potential dilution and concerns about corporate governance and accountability for past performance.

Positives

• The repricing significantly reduces the exercise price for Scott Juda, making the options more 'in-the-money' or reducing their 'out-of-the-money' status.
• This action could serve as an incentive for the director, potentially re-aligning his interests with future stock price appreciation from the new, lower base.

Negatives

• Stock option repricing can be viewed negatively by existing shareholders as it effectively grants new options at a lower price, potentially diluting their ownership or reducing the incentive for management to achieve higher stock prices.
• The repricing suggests that the original exercise prices were significantly above the current market price, indicating poor past stock performance relative to the original grant dates.
• The company's stock price on the repricing date ($1.50) is substantially lower than many of the original exercise prices (e.g., $24.82, $17.49), reflecting a significant decline in value.

Risks

• Shareholder Dilution: The repricing of options at a lower strike price increases the likelihood of these options being exercised, potentially leading to dilution for existing shareholders if new shares are issued.
• Perception of Poor Governance: Stock option repricing, especially when the stock price has fallen significantly, can be perceived as a reward for underperformance and may raise concerns about corporate governance and management accountability.
• Reduced Incentive Alignment: While intended to re-incentivize, frequent repricing can signal to management that poor performance will be 'fixed' by the board, potentially reducing the long-term incentive to drive sustained stock price growth.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the terms of the repriced options.

Industry Context

Stock option repricing often occurs in industries where company stock prices have experienced significant declines, making previously granted options 'underwater' (exercise price higher than market price). Companies may reprice options to restore their incentive value for key personnel, particularly in sectors like biotechnology where stock performance can be volatile due to clinical trial results and regulatory approvals. This practice aims to retain and motivate executives and directors by re-aligning their equity incentives with current market realities, though it can be controversial among shareholders.

Comparison to Industry Standards

• Option repricing is a practice that has seen varying levels of acceptance across industries. While some companies, particularly in volatile sectors like biotech, use it to re-incentivize management after significant stock price drops, it is generally viewed with skepticism by corporate governance advocates.
• Compared to companies with strong governance practices, frequent or significant repricing can be seen as a red flag, as it can dilute shareholder value and reward management for underperformance rather than sustained growth.
• Companies like Apple or Microsoft, known for strong stock performance, rarely engage in such broad repricing, preferring to issue new grants or use performance-based awards to incentivize executives.
• In the biotech sector, companies such as Biogen or Gilead Sciences, when facing pipeline setbacks and stock declines, might consider such measures, but often face investor backlash if not clearly justified by strategic shifts or exceptional circumstances.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential dilution if repriced options are exercised, and a negative perception regarding corporate governance and past stock performance.
• Employees (other option holders): If this repricing extends to other employees, it could boost morale and retention by restoring incentive value to their options.
• Director (Scott Juda): Significantly benefits from the lower exercise price, restoring the incentive value of his options.

Next Steps

• The repriced options will become exercisable in accordance with their original vesting schedules.
• The reporting person's continued service with the Issuer is required for vesting.

Key Dates

Recommendation

While the repricing of director stock options to a significantly lower strike price reflects past underperformance and raises corporate governance concerns, it also re-incentivizes a key director. This action, approved by stockholders, suggests an attempt to re-align management incentives. However, the underlying reason for the repricing (a substantial drop in stock price) indicates fundamental challenges. Without further information on the company's operational performance or strategic outlook, a 'hold' recommendation is prudent. Investors should monitor future financial results and strategic developments to assess if the re-incentivized management can drive a sustained recovery.

Keywords

Inmune Bio, INMB, Stock Options, Option Repricing, SEC Form 4, Beneficial Ownership, Director Compensation, Equity Incentive Plan, Corporate Governance